Human Intracranial Electrophysiology
Dartmouth-Hitchcock Medical Center · with Dartmouth College · NCT05529264
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 175
- US sites recruiting
- 1
- Study start
- January 17, 2023
- Record last updated
- January 15, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study will enroll patients with epilepsy who are being evaluated for epilepsy surgery and have electrodes implanted in the brain and/or have electrodes on the scalp. Additionally, this study will recruit normal and online controls (participants who do not have epilepsy). Participants will be asked to participate in 1 to 2 (30-90 minutes) daily sessions designed to test aspects of human cognition such as memory, speech, language, feeling, movement, attention, sound perception, and emotions. Generally, this will involve working on a computer, looking at pictures or watching videos, and answering questions. Additionally, participants may be asked to be hooked up to additional equipment such as eye tracker, electrical stimulator, heart rate monitor, sweat monitor or other non-invasive equipment. The overall aim of this study is to use human intracranial electrophysiology (the recording of the electrical activity of the human brain) to study localization and function of the human brain.
Being studied: Memory Tasks; Attention/arousal tasks; Language tasks; Visuospatial tasks; Auditory Tasks; Brain Stimulation; Social Emotional Task; Recording of facial expressions; Judgement/Impulsivity Task
Conditions: Epilepsy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Patients with Intracranial EEG: Inclusion Criteria
- Patients must be age 18 years or older. There is no upper age limit.
- Patients must have a diagnosis of refractory epilepsy undergoing intracranial EEG recording for clinical purposes.
Patients with Intracranial EEG: Exclusion Criteria
- Patient has additional neurological condition (such as stroke or dementia) or a psychiatric condition (such as active psychosis or suicidal ideation) and are deemed inappropriate for the study
- Patients are not able to provide informed consent for any reason (e.g. encephalopathic, experiencing a seizure)
Patients with Scalp EEG: Inclusion Criteria
- Patients must be age 18 years or older. There is no upper age limit.
- Patients must have a probable diagnosis of epilepsy.
Patients with Scalp EEG: Exclusion Criteria
- Patient has additional neurological condition (such as stroke or dementia) or a psychiatric condition (such as active psychosis or suicidal ideation) and are deemed inappropriate for the study
- Patients are not able to provide informed consent for any reason (e.g. encephalopathic, experiencing a seizure)
Normal Controls: Inclusion Criteria
- Participants must be age 18 years or older. There is no upper age limit.
- Participants must be able to provide informed consent for themselves.
Normal Controls: Exclusion Criteria
- Determined not to be appropriate normal control for the study population
Recruiting US locations
Dartmouth-Hitchcock Medical Center
Lebanon, NH 03776
Site contact: Krzysztof A Bujarski, MD · 603 650-5104 · krzysztof.a.bujarski@hitchcock.org
Study contacts (from the official record)
- Krzysztof A Bujarski, MD · 603-650-5104 · krzysztof.a.bujarski@hitchcock.org
- Gina Kersey · (603) 650-0260 · Gina.E.Kersey@Hitchcock.ORG
Similar studies in New Hampshire
All neurology studies in New Hampshire →- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Nashua, NH + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Lebanon, NH + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Nashua, NH + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Kedrion S.p.A.
- Location
- Lebanon, NH + 4 other US sites
- Eligibility basics
- Ages 18+